LMDP10
LMDP10 is an orally active 3-amino quinazoline derivative with Keap1-Nrf2 pathway activation activity. LMDP10 binds to Keap1 to inhibit Keap1-Nrf2 interaction, thereby activating the Nrf2 pathway. LMDP10 elevates Nrf2, SOD, and GSH levels, reduces MDA and TNF-α levels, attenuates neurodegeneration, and improves memory function in Alzheimer’s disease (AD) rats. LMDP10 can be used for the study of AD[1].
Product Specifications
CAS Number
2760446-25-9
UNSPSC
12352005
Target
Drug Derivative; Keap1-Nrf2
Related Pathways
NF-κB; Others
Field of Research
Neurological Disease
Smiles
O=C(N(CC(N1NC(C2=CC=CC=C2)=O)=NC3=C(C=CC=C3)C1=O)C4=CC=C(F)C=C4)C5=CC=CC=C5
Molecular Formula
C29H21FN4O3
Molecular Weight
492.50
References & Citations
[1]Maheta P, et al. Neuroprotective Effects of a 3-Amino Quinazoline Derivative via Keap1-Nrf2 Pathway Activation in an ICV-STZ-Induced Rat Model of Sporadic Alzheimer's Disease. ACS Chem Neurosci. 2025 Sep 17;16 (18) :3611-3622.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC471731-100 1x 100 µL
Chromogranin A / CHGA (Neuroendocrine Marker) (CHGA/1731R), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
TRC-E414265-25MG 25 mg
10-((Ethoxycarbonyl)oxy)-10-oxodecanoic Acid
Sign In for Pricing
View Details 